Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative drugs operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these agents increase insulin release and suppress glucagon sec

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing variations in their p